Department of Obstetrics, Gynecology, and Reproductive Biology, College of Human Medicine, Michigan State University, East Lansing, MI, USA.
Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Hum Reprod. 2022 Oct 31;37(11):2672-2689. doi: 10.1093/humrep/deac196.
STUDY QUESTION: Is there an association between fertility status, method of conception and the risks of birth defects and childhood cancer? SUMMARY ANSWER: The risk of childhood cancer had two independent components: (i) method of conception and (ii) presence, type and number of birth defects. WHAT IS KNOWN ALREADY: The rarity of the co-occurrence of birth defects, cancer and ART makes studying their association challenging. Prior studies have indicated that infertility and ART are associated with an increased risk of birth defects or cancer but have been limited by small sample size and inadequate statistical power, failure to adjust for or include plurality, differences in definitions and/or methods of ascertainment, lack of information on ART treatment parameters or study periods spanning decades resulting in a substantial historical bias as ART techniques have improved. STUDY DESIGN, SIZE, DURATION: This was a population-based cohort study linking ART cycles reported to the Society for Assisted Reproductive Technology Clinic Outcome Reporting System (SART CORS) from 1 January 2004 to 31 December 2017 that resulted in live births in 2004-2018 in Massachusetts and North Carolina and live births in 2004-2017 in Texas and New York. A 10:1 sample of non-ART births were chosen within the same time period as the ART birth. Non-ART siblings were identified through the ART mother's information. Children from non-ART births were classified as being born to women who conceived with ovulation induction or IUI (OI/IUI) when there was an indication of infertility treatment on the birth certificate, and the woman did not link to the SART CORS; all others were classified as being naturally conceived. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study population included 165 125 ART children, 31 524 non-ART siblings, 12 451 children born to OI/IUI-treated women and 1 353 440 naturally conceived children. All study children were linked to their respective State birth defect registries to identify major defects diagnosed within the first year of life. We classified children with major defects as either chromosomal (i.e. presence of a chromosomal defect with or without any other major defect) or nonchromosomal (i.e. presence of a major defect but having no chromosomal defect), or all major defects (chromosomal and nonchromosomal), and calculated rates per 1000 children. Logistic regression models were used to generate adjusted odds ratios (AORs) and 95% CIs of the risk of birth defects by conception group (OI/IUI, non-ART sibling and ART by oocyte source and embryo state) with naturally conceived children as the reference, adjusted for paternal and maternal ages; maternal race and ethnicity, education, BMI, parity, diabetes, hypertension; and for plurality, infant sex and State and year of birth. All study children were also linked to their respective State cancer registries. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% CIs of cancer by birth defect status (including presence of a defect, type and number of defects), and conception group. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 29 571 singleton children (2.0%) and 3753 twin children (3.5%) had a major birth defect (chromosomal or nonchromosomal). Children conceived with ART from autologous oocytes had increased risks for nonchromosomal defects, including blastogenesis, cardiovascular, gastrointestinal and, for males only, genitourinary defects, with AORs ranging from 1.22 to 1.85; children in the autologous-fresh group also had increased risks for musculoskeletal (AOR 1.28, 95% CI 1.13, 1.45) and orofacial defects (AOR 1.40, 95% CI 1.17, 1.68). Within the donor oocyte group, the children conceived from fresh embryos did not have increased risks in any birth defect category, whereas children conceived from thawed embryos had increased risks for nonchromosomal defects (AOR 1.20, 95% CI 1.03, 1.40) and blastogenesis defects (AOR 1.74, 95% CI 1.14, 2.65). The risk of cancer was increased among ART children in the autologous-fresh group (HR 1.31, 95% CI 1.08, 1.59) and non-ART siblings (1.34, 95% CI 1.02, 1.76). The risk of leukemia was increased among children in the OI/IUI group (HR 2.15, 95% CI 1.04, 4.47) and non-ART siblings (HR 1.63, 95% CI 1.02, 2.61). The risk of central nervous system tumors was increased among ART children in the autologous-fresh group (HR 1.68, 95% CI 1.14, 2.48), donor-fresh group (HR 2.57, 95% CI 1.04, 6.32) and non-ART siblings (HR 1.84, 95% CI 1.12, 3.03). ART children in the autologous-fresh group were also at increased risk for solid tumors (HR 1.39, 95% CI 1.09, 1.77). A total of 127 children had both major birth defects and cancer, of which 53 children (42%) had leukemia. The risk of cancer had two independent components: (i) method of conception (described above) and (ii) presence, type and number of birth defects. The presence of nonchromosomal defects increased the cancer risk, greater for two or more defects versus one defect, for all cancers and each type evaluated. The presence of chromosomal defects was strongly associated with cancer risk (HR 8.70 for all cancers and HR 21.90 for leukemia), further elevated in the presence of both chromosomal and nonchromosomal defects (HR 21.29 for all cancers, HR 64.83 for leukemia and HR 4.71 for embryonal tumors). Among the 83 946 children born from ART in the USA in 2019 compared to their naturally conceived counterparts, these risks translate into an estimated excess of 761 children with major birth defects, 31 children with cancer and 11 children with both major birth defects and cancer. LIMITATIONS, REASONS FOR CAUTION: In the SART CORS database, it was not possible to differentiate method of embryo freezing (slow freezing versus vitrification), and data on ICSI were only available in the fresh embryo ART group. In the OI/IUI group, it was not possible to differentiate type of non-ART treatment utilized, and in both the ART and OI/IUI groups, data were unavailable on duration of infertility. Since OI/IUI is underreported on the birth certificate, some OI/IUI children were likely included among the naturally conceived children, which will decrease the difference between all the groups and the naturally conceived children. WIDER IMPLICATIONS OF THE FINDINGS: The use of ART is associated with increased risks of major nonchromosomal birth defects. The presence of birth defects is associated with greater risks for cancer, which adds to the baseline risk in the ART group. Although this study does not show causality, these findings indicate that children conceived with ART, non-ART siblings, and all children with birth defects should be monitored more closely for the subsequent development of cancer. STUDY FUNDING/COMPETING INTEREST(S): This project was supported by grant R01 HD084377 from the National Institute of Child Health and Human Development. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Child Health and Human Development, or the National Institutes of Health, nor any of the State Departments of Health which contributed data. M.L.E. reports consultancy for Ro, Hannah, Dadi, Sandstone and Underdog; presidency of SSMR; and SMRU board member. The remaining authors report no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
研究问题:生育状况、受孕方式与出生缺陷和儿童癌症风险之间是否存在关联?
摘要回答:儿童癌症风险有两个独立的组成部分:(i)受孕方式,和(ii)存在、类型和数量的出生缺陷。
已知情况:ART 中出生缺陷、癌症和 ART 的罕见共同发生使得研究它们之间的关联具有挑战性。先前的研究表明,不孕和 ART 与出生缺陷或癌症的风险增加有关,但由于样本量小且统计效力不足,未能进行调整以包括多胎妊娠、差异定义和/或方法的确定、ART 治疗参数或研究期间的信息缺乏,以及 ART 技术的实质性历史偏差,因为自 2004 年以来,ART 技术已经得到了改善。
研究设计、规模、持续时间:这是一项基于人群的队列研究,通过 2004 年至 2017 年在马萨诸塞州和北卡罗来纳州以及 2004 年至 2017 年在德克萨斯州和纽约州进行的 SART CORS 报告的 ART 周期,将其与 2004-2018 年活产相关联。ART 分娩的同期选择了 10:1 的非-ART 分娩样本。非-ART 兄弟姐妹是通过 ART 母亲的信息确定的。非-ART 分娩的儿童被归类为在出生证明上有生育治疗指征的情况下,由排卵诱导或 IUI(OI/IUI)受孕的妇女所生,如果该妇女与 SART CORS 没有联系,则被归类为自然受孕。
参与者/材料、设置、方法:研究人群包括 165125 名 ART 儿童、31524 名非-ART 兄弟姐妹、12451 名接受 OI/IUI 治疗的妇女所生的儿童和 1353440 名自然受孕的儿童。所有研究儿童均与各自的州出生缺陷登记处链接,以确定在生命的第一年诊断出的主要缺陷。我们将有主要缺陷的儿童分类为染色体(即存在染色体缺陷,伴有或不伴有任何其他主要缺陷)或非染色体(即存在主要缺陷,但不存在染色体缺陷),或所有主要缺陷(染色体和非染色体),并计算每 1000 名儿童的发生率。使用逻辑回归模型生成调整后的比值比(AOR)和 95%置信区间(CI),以通过受孕方式(OI/IUI、非-ART 兄弟姐妹和卵母细胞源和胚胎状态的 ART)和自然受孕的儿童作为参考,调整父亲和母亲的年龄;母亲的种族和民族、教育、BMI、多胎妊娠、糖尿病、高血压;以及多胎妊娠、婴儿性别和州及出生年份。所有研究儿童还与各自的州癌症登记处链接。使用 Cox 比例风险回归模型估计按出生缺陷状态(包括存在缺陷、类型和数量)和受孕方式划分的癌症的风险比(HR)和 95%CI。
主要结果和机会的作用:共有 29571 名(2.0%)单胎儿童和 3753 名(3.5%)双胞胎儿童患有主要出生缺陷(染色体或非染色体)。从自体卵母细胞获得的 ART 儿童具有非染色体缺陷的风险增加,包括胚细胞发生、心血管、胃肠道和仅男性的泌尿生殖系统缺陷,AOR 范围为 1.22 至 1.85;自体-新鲜组的儿童也具有增加的肌肉骨骼(AOR 1.28,95%CI 1.13,1.45)和口面(AOR 1.40,95%CI 1.17,1.68)缺陷的风险。在供体卵母细胞组中,从新鲜胚胎获得的胚胎受孕的儿童在任何出生缺陷类别中均未增加风险,而从解冻胚胎受孕的儿童则具有非染色体缺陷(AOR 1.20,95%CI 1.03,1.40)和胚细胞发生缺陷(AOR 1.74,95%CI 1.14,2.65)的风险增加。在自体-新鲜组和非-ART 兄弟姐妹中,ART 儿童的癌症风险增加(HR 1.31,95%CI 1.08,1.59)。在 OI/IUI 组和非-ART 兄弟姐妹中,儿童患白血病的风险增加(HR 2.15,95%CI 1.04,4.47)。ART 儿童在自体-新鲜组(HR 1.68,95%CI 1.14,2.48)和供体-新鲜组(HR 2.57,95%CI 1.04,6.32)中患中枢神经系统肿瘤的风险增加,非-ART 兄弟姐妹(HR 1.84,95%CI 1.12,3.03)。ART 儿童在自体-新鲜组(HR 1.39,95%CI 1.09,1.77)中患实体肿瘤的风险也增加。共有 127 名儿童同时患有主要出生缺陷和癌症,其中 53 名(42%)患有白血病。癌症的风险有两个独立的组成部分:(i)受孕方式(如上所述)和(ii)存在、类型和数量的出生缺陷。存在非染色体缺陷会增加癌症风险,两个或更多缺陷的风险大于一个缺陷,所有癌症和每种评估的癌症类型均如此。存在染色体缺陷与癌症风险密切相关(所有癌症的 HR 8.70,白血病的 HR 21.90),并且存在染色体和非染色体缺陷时风险进一步升高(所有癌症的 HR 21.29,白血病的 HR 64.83,胚胎性肿瘤的 HR 4.71)。与美国 2019 年在 ART 中出生的 83946 名儿童相比,与自然受孕的儿童相比,这些风险预计会导致大约 761 名儿童出现主要出生缺陷、31 名儿童患有癌症和 11 名儿童同时患有主要出生缺陷和癌症。
局限性、谨慎的原因:在 SART CORS 数据库中,无法区分胚胎冷冻方法(慢速冷冻与玻璃化),并且新鲜胚胎 ART 组中仅提供 ICSI 数据。在 OI/IUI 组中,无法区分所使用的非 ART 治疗类型,ART 和 OI/IUI 组中均无法获得不孕持续时间的数据。由于 OI/IUI 在出生证明上的报告率较低,因此一些 OI/IUI 儿童可能被包括在自然受孕的儿童中,这将降低所有组与自然受孕的儿童之间的差异。
更广泛的影响:ART 的使用与主要非染色体出生缺陷的风险增加有关。存在出生缺陷与癌症风险增加有关,这增加了 ART 组的基线风险。尽管本研究没有显示因果关系,但这些发现表明,ART 儿童、非-ART 兄弟姐妹和所有有出生缺陷的儿童应更密切监测随后的癌症发展。
项目资助/利益冲突:本项目由美国国立儿童健康与人类发育研究所的 R01 HD084377 资助。内容仅由作者负责,不一定代表国立儿童健康与人类发育研究所、国立卫生研究院或参与数据提供的州卫生部的官方观点。M.L.E. 报告了 Ro、Hannah、Dadi、Sandstone 和 Underdog 的咨询;SSMR 主席;SMRU 董事会成员。其余作者报告没有利益冲突。
试验注册:无。
Hum Reprod. 2021-1-1
MMWR Surveill Summ. 2014-11-21
MMWR Surveill Summ. 2015-8-14
Reprod Biomed Online. 2025-6
Arch Dis Child. 2024-12-13
MMWR Surveill Summ. 2022-2-18
Kidney Int Rep. 2021-1-10
Fertil Steril. 2021-8
Natl Vital Stat Rep. 2021-4
Hum Reprod. 2021-1-1